Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a variant form of U1 small nuclear RNA encoded by a pseudogene (class I U1 snRNA pseudogene). While classical U1 snRNA is a core element of the spliceosome that recognizes 5′ splice sites and initiates spliceosome assembly, variant U1 snRNAs—including those previously thought to arise from pseudogenes—have been shown to be transcribed, processed, and assembled into ribonucleoprotein complexes. Some variant U1 snRNAs can regulate expression of subsets of target genes through pre-mRNA processing, especially in developmentally controlled contexts. However, these variants are not established therapeutic targets or disease-related entities[3]. Key details: - Variant U1 snRNAs (vU1) are transcribed from loci historically annotated as pseudogenes. These "imperfect" copies can form unique ribonucleoprotein particles and function in the regulation of gene expression, especially in pre-mRNA processing[3]. - U1 snRNA variants may affect transcriptome integrity by modulating alternative polyadenylation and exon choice, but their individual functions (including RNVU1-23/RNU1-92P) are not well characterized, and they do not encode proteins[1][3]. - The molecular family is noncoding small nuclear RNA, not a receptor, enzyme, nor transporter. - Nomenclature is variable; the gene is frequently called by its database ID (e.g., RNU1-92P if corresponding), and variants are distinguished by number or annotation—RNVU1-23 is non-standard but might correspond to a cataloged pseudogene. Summary: RNA, variant U1 small nuclear 23 (RNVU1-23, RNU1-92P) is a pseudogene-expressed, noncoding RNA with functions in pre-mRNA processing and transcriptome regulation. It is not a recognized therapeutic target, and its nomenclature is non-standard and potentially ambiguous[3][2][5].
Null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, variant U1 small nuclear 23 (RNVU1-23).